volume in the border region (0.04 ± 0.006 μm³ in border vs 0.01 ± 0.002 μm³ in remote; p < 0.001).

Our research shows remodelling of the t-tubule network in the post-MI sheep myocardium. We noted reduced t-tubule count, t-tubule fragmentation, and dilation of remaining t-tubules. Importantly our work shows that these changes occur in a regional manner, being most pronounced in the border region. These changes may reflect regional wall stresses post-MI, and we speculate that our observations may result in region-specific changes to systolic calcium and contractility post-MI.

Conflict of Interest Authors declare that there is no conflict of interest.

A CARVEDILOL ANALOGUE, VKII-86, PREVENTS INHIBITION OF VEGF SIGNALLING MITIGATES THE HEART

Results Dantrolene significantly reduced the incidence of venous-embolism (p<0.01) and posterior cardinal vein (PCV) (wt 25.4 ± 0.9 μm, mut 26.1 ± 0.4 μm, p<0.001). Consequently, blood flow is shunted directly from the DA to the PCV, bypassing intersegmental vessels, recapitulating the AVM phenotype of HHT. Treatment of engmu130 embryos with the VEGF receptor tyrosine kinase inhibitor Tivozanib prevented enlarged major vessels in engmu130 mutants; DA (wt+Tivozanib 21.8 ± 0.8 μm, mut+Tivozanib 23.2 ± 0.6 μm) and PCV (wt+Tivozanib 24.4 ± 0.4 μm, mut+Tivozanib 26.1 ± 0.6 μm). Inhibiting eNOS and p38MAPK had no detectable effect, whilst inhibiting TOR or MEK prevented the enlarged vessel phenotype. Combining subtherapeutic doses of both TOR and MEK inhibitors also prevented vessel enlargement, suggesting synergy between these pathways.

Conclusion The HHT-like phenotype of zebrafish eng mutants can be mitigated by inhibition of the TOR and MEK pathways of VEGF signalling. These represent potential therapeutic targets in HHT.

Conflict of Interest The authors declare that there is no conflict of interest.

A10

INHIBITION OF VEGF SIGNALLING MITIGATES THE HEREDITARY HAEMORRHAGIC TELANGIECTASIA-LIKE PHENOTYPE IN ENDMGLIN MUTANT ZEBRAFISH

1Ryan Snodgrass, 2Tim Chico, 3Helen Arthur. 1University of Sheffield, Sheffield, UK; 2Newcastle University

Introduction Hereditary haemorrhagic telangiectasia (HHT) is characterised by arteriovenous malformations (AVMs). Large AVMs may affect lungs, liver and brain, whilst telangiectases in mucocutaneous tissues are prone to haemorrhage. HHT type I is caused by loss-of-function ENG mutations. There is growing evidence targeting VEGF signalling is beneficial in HHT. However, VEGF signalling is complex and drives numerous downstream pathways, and it is not clear which are critical to target. We therefore pharmacologically inhibited either global VEGF signalling or components of downstream pathways in zebrafish eng mutants to determine which pathways drive the HHT phenotype.

Methods We studied zebrafish in a Tg(kdrl:Hsa.HRASmCherry)s916 background which fluorescently labels endothelial cells. The effect of engmu130 mutation and/or 24hr treatment with VEGF pathway inhibitors on vascular development was quantified by lightsheet fluorescence microscopy in 3d post-fertilisation embryos (10-15/group).

Results engmu130 embryos had a significantly enlarged dorsal aorta (DA) diameter (wt 22.3 ± 0.9 μm, mut 26.1 ± 0.3 μm, p<0.01) and posterior cardinal vein (PCV) (wt 25.4 ± 0.4 μm, mut 29.1 ± 0.4 μm, p<0.001). Consequently, blood flow is shunted directly from the DA to the PCV, bypassing intersegmental vessels, recapitulating the AVM phenotype of HHT. Treatment of engmu130 embryos with the VEGF receptor tyrosine kinase inhibitor Tivozanib prevented enlarged major vessels in engmu130 mutants; DA diameter (wt+Tivozanib 21.8 ± 0.8 μm, mut+Tivozanib 23.2 ± 0.6 μm) and PCV (wt+Tivozanib 24.4 ± 0.4 μm, mut+Tivozanib 26.1 ± 0.6 μm). Inhibiting eNOS and p38MAPK had no detectable effect, whilst inhibiting TOR or MEK prevented the enlarged vessel phenotype. Combining subtherapeutic doses of both TOR and MEK inhibitors also prevented vessel enlargement, suggesting synergy between these pathways.

Conclusion The HHT-like phenotype of zebrafish eng mutants can be mitigated by inhibition of the TOR and MEK pathways of VEGF signalling. These represent potential therapeutic targets in HHT.

Conflicts of Interest None

BS10

A CARVEDILOL ANALOGUE, VKII-86, PREVENTS HYPOKALAEMIA-INDUCED VENTRICULAR ARRHYTHMIA THROUGH NOVEL MULTI-CHANNEL EFFECTS

1Victoria Robinson, 2Izzeddin Alsalahat, 3Sally Freeman, 4Charles Antzelevitch, 5Hector Barajas-Martinez, 6Luigi Venetucci. 1The University of Manchester, Manchester, UK; 6The Lankenau Institute for Medical Research

Background and Purpose Hypokalaemia is the most common electrolyte disturbance with a significant mortality due to the occurrence of ventricular arrhythmia. There is currently no available treatment to prevent ventricular arrhythmia in patients susceptible to hypokalaemia, such as those with heart failure. Potassium supplementation alone is not sufficient to alter mortality. QT prolongation and intracellular Ca2+ loadings are associated with subsequent diastolic Ca2+ release via ryanodine receptors (RyR2) are considered the predominant arrhythmo-genic mechanisms in hypokalaemia-induced ventricular arrhythmia. We investigated the antiarrhythmic actions of two RyR2 inhibitors: dantrolene and VKII-86, a carvedilol analogue with no β-blocking activity, in hypokalaemia.

Methods Surface ECG and ventricular action potentials (APs) were recorded from whole-heart murine Langendorff preparations. Ventricular arrhythmia incidence was compared in hearts perfused with low [K+] and those pre-treated with dantrolene or VKII-86. Whole-cell patch clamping was used in murine and canine ventricular cardiomyocytes to study the effects of dantrolene and VK-II-86 on AP parameters in normokalaemic conditions. Hypokalaemia was associated with a significant reduction of IK1 and IKr, and a significant increase in INa,L and Ica. VK-II-86 prevented all hypokalaemia-induced changes in ion-channel activity (p<0.05 in each case).

Conclusions and Implications VKII-86 prevents hypokalaemia-induced arrhythmogenesis by normalising intracellular calcium homeostasis and repolarization reserve. The fact that VKII-86 does not have beta-blocking activity and does not alter AP parameters in normo [K+] is promising for future tolerability and electrophysiological drug safety testing, respectively. This unique pharmacological profile may provide an exciting treatment option in hypokalaemia and other arrhythmias caused by delayed repolarization or Ca2+ overload such as heart failure and the Long QT Syndromes.

Conflict of Interest None

BS11

INHIBITION OF VEGF SIGNALLING MITIGATES THE HEREDITARY HAEMORRHAGIC TELANGIECTASIA-LIKE PHENOTYPE IN ENDMGLIN MUTANT ZEBRAFISH

1The University of Manchester, Manchester, UK

Authors declare that there is no conflict of interest.